SlideShare uma empresa Scribd logo
1 de 46
ROLE OF RADIATION IN SMALL CELL
LUNG CANCER
Dr Bharti Devnani
Moderator:- Dr Sheh Rawat
Staging of SCLC depends on radiation portals
(Veteran’s administration lung group)
Limited Stage
Disease confined to I/L hemithorax which could be
safely encompassed with in a tolerable RT field.
T1, T2, nonmetastatic
 Contralateral mediastinal and I/L SCF
Extensive stage
Beyond I/L hemithorax
T3,T4 and metastatic disease
Definitive (For LS)
Thoracic radiation as a part of CCRT
Adjuvant RT
Node positive cases after lobectomy
Prophylactic cranial irradiation
Palliative EXRT
Thoracic
Brain mets
Bone mets
Oncologic emergencies
SVCO
Spinal cord compression
Palliative brachytherapy
Endobronchial brachytherapy: Hemoptysis
ROLE OF THORACIC RADIATION IN
LIMITED STAGE
EVOLUTION
Before the introduction of chemo in 1970,
RT was the mainstay of treatment
CT
More local recurrences with chemo alone
CT+RT-Standarad of care
EVIDENCE FOR THORACIC RADIOTHERAPY
25-30% reduction in the local recurrence with 5-7% increase in 2 year survival
with addition of radiotherapy
Pignon et al NEJM 1992 327;1618-24
ISSUES IN THORACIC RT OF SCLC
 Sequencing with chemotherapy
(concurrent v/s sequential)
 Timing of RT
(Early v/s late)
 Portals
(before chemotherapy v/s shrinking field)
 Dose and fractionation schedules
(conventional v/s hyperfractionation)
ISSUES IN THORACIC RT OF SCLC
 Sequencing with chemotherapy
(concurrent v/s sequential)
 Timing of RT
(Early v/s late)
 Portals
(before chemotherapy v/s shrinking field)
 Dose and fractionation schedules
(conventional v/s hyperfractionation)
Takada et al.J Clin Oncol 2002; 20:3054-60.
Better outcome with CCT with a trend towards improved OS.
Concurrent RT reduces the risk of tumor repopulation and
development of resistant clones.
Radiosensitizing effect
ISSUES IN THORACIC RT OF SCLC
 Sequencing with chemotherapy
(concurrent v/s sequential)
 Timing of RT
(Early v/s late)
 Portals
(before chemotherapy v/s shrinking field)
 Dose and fractionation schedules
(conventional v/s hyperfractionation)
Benefit in 2 year survival rate with early RT(within 9 weeks or before 3rd cycle)
Factors which have significant impact on the benefit
of early RT were:-
 Type of chemotherapy
 The fractionation scheme
Concept of SER
Start of any treatment
until the end of
radiotherapy
Cancer Treat Rev 2007; 33:461-73.
 Significant 2 & 5 years improvement in survival when
RT was started within 30 days of platinum based chemo
(2-year survival: HR: 0.73, 5-year survival: HR: 0.65).
 This was even more pronounced when the overall
treatment time of chest radiotherapy was less than 30
days.
Early and concurrent chemoradiation is preferred over
late and sequential schedule.
ISSUES IN THORACIC RT OF SCLC
 Sequencing with chemotherapy
(concurrent v/s sequential)
 Timing of RT
(Early v/s late)
 Dose and fractionation schedules
(conventional v/s hyperfractionation)
 Portals
(before chemotherapy v/s shrinking field)
High chances of local recurrence with conventional
RT, attempts made to improve the outcome by:-
Hyperfractionated
Accelerated
radiotherapy
Dose escalation
417 patients LS-
SCLC
45 Gy at 1.5
Gy/#B.D.x3weeks
45 Gy/25# at 1.8
Gy/# x5 weeks
Grade -3
Esophagitis
(27%v/s 11%)
P<0.001
ONGOING TRIALS (HYPERFRACTIONATION &
DOSE ESCALATION)
ISSUES IN THORACIC RT OF SCLC
 Sequencing with chemotherapy
(concurrent v/s sequential)
 Timing of RT
(Early v/s late)
 Dose and fractionation schedules
(conventional v/s hyperfractionation)
 Portals
(before chemotherapy v/s shrinking field)
RT PORTALS
 PET based planning should be used. (PET at the
time of radiotherapy planning or within 4 weeks)
 GTV = Post induction chemotherapy volume
 Omission of elective nodal irradition.
 Low rates of local recurrence(11% with only CT
based planning, 3 % with PET based planning)
 Decreases the esophageal toxicity significantly.
ROLE OF THORACIC RT IN
EXTENSIVE STAGE
CR at distant sites and
any response at local
site (n=210)
CT
+
RT= 54 Gy/36#
CT alone
Median survival-17 months v/s 11 months
Survival rate at 3 years-22% v/s 13%
Survival rate at 5 years-9% v/s 4%
PROPHYLACTIC CRANIAL
IRRADIATION
Rationale
 Frequent brain mets in SCLC
 20 %- at diagnosis
 80%- during the course of the disease
 Once symptomatic- results have been poor.
Incidence of brain metastasis decreased by 25% at 3 years (58.6% v/s
33.3%)
5.4 % survival benefit with addition of PCI
PCI IN EXTENSIVE STAGE DISEASE
14.6 % v/s
40.4%
27.1% v/s 13.3%
at 1 yr
DOSE OF PCI
Limited stage
25 Gy/10#
24 Gy/8#
30Gy/15#
Extensive stage
25 Gy/10#
Shorter fractionation scheme of 20 Gy/5# can be
used.
Dose>30 Gy should be avoided due to high risk of
neurotoxicity
ROLE OF RT IN ADJUVANT SETTING
ROLE OF RT IN PALLIATION (EXRT)
RADIATION FOR BRAIN METASTASIS
WBRT- 30Gy/10#
BONE METS & PATHOLOGICAL FRACTURE
30 Gy/10#
20Gy/5#
24Gy/6#
8 Gy single fraction
ROLE OF RADIATION IN ONCOLOGIC
EMERGENCIES IN SCLC
SPINAL CORD COMPRESSION
30Gy/10#
SUPERIOR VENA CAVA OBSTRUCTION
 Symptomatic relief in
70-90% cases with
radiotherapy alone.
 Dose- initial high dose
fractionation of 3- 4 Gy
followed by 1.8 Gy
fractionation
ROLE OF ENDOBRONCIAL
BRACHYTHERAPY - HEMOPTYSIS
TAKE HOME MESSAGE
LS-SCLC
Concurrent CCT/RT
Early(1st or 2nd cycle)
Dose-45 Gy @1.5 Gy bd or 50-60 Gy @1.8 Gy once daily
Any response to chemo-PCI to a dose of 25 Gy/10#
ES-SCLC
Any response to chemo- PCI-25 Gy/10# or shorter 20 Gy/5#
can be used.
Possible value of local RT are the subject of ongoing
investigation.
Palliation
Thank U
 Santa air hostess se-aapki shakal meri biwi se milti
hai
 Air hostess ne zordar thappad santa k muh pe
mara
 Santa- Kamal hai, Aadat bhi milti hai
Very Touchy story:
"Husband forgot to wish her on his Wife's birthday.
He came home late at night from the office .....
His wife shouted: How would u feel if u dont see me
for next few days?
He couldnt believe his luck. He replied at once.''
Wowww.....That would be great..!''
Monday passed & he didn't see her.
Tuesday he didnt see her
.
.
& wednesday passed too
.
.
On Thursday the swelling was better & he could
see her from the corner of his left eye...

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Quantec dr. upasna saxena (2)
Quantec   dr. upasna saxena (2)Quantec   dr. upasna saxena (2)
Quantec dr. upasna saxena (2)
 
Hypofractionated Radiation Therapy in Breast Cancer
Hypofractionated Radiation Therapy in Breast CancerHypofractionated Radiation Therapy in Breast Cancer
Hypofractionated Radiation Therapy in Breast Cancer
 
Srs and sbrt 2 dr.kiran
Srs and sbrt 2 dr.kiranSrs and sbrt 2 dr.kiran
Srs and sbrt 2 dr.kiran
 
Hypofractionation in carcinoma prostate
Hypofractionation in carcinoma prostateHypofractionation in carcinoma prostate
Hypofractionation in carcinoma prostate
 
Craniospinal irradiation
Craniospinal irradiationCraniospinal irradiation
Craniospinal irradiation
 
Gap correction
Gap correctionGap correction
Gap correction
 
Embrace ii protocol
Embrace ii protocolEmbrace ii protocol
Embrace ii protocol
 
BOOK ON REIRRADIATION
BOOK ON REIRRADIATIONBOOK ON REIRRADIATION
BOOK ON REIRRADIATION
 
QUANTEC
QUANTECQUANTEC
QUANTEC
 
Role of SBRT in lung cancer
Role of SBRT in lung cancerRole of SBRT in lung cancer
Role of SBRT in lung cancer
 
TSET
TSETTSET
TSET
 
Icru – 83 dr. upasna
Icru – 83  dr. upasnaIcru – 83  dr. upasna
Icru – 83 dr. upasna
 
RT breast apbi
RT breast apbiRT breast apbi
RT breast apbi
 
Radiotherapy in ca esophagus
Radiotherapy in ca esophagusRadiotherapy in ca esophagus
Radiotherapy in ca esophagus
 
Radiation therapy in prostate cancer
Radiation therapy in prostate cancer Radiation therapy in prostate cancer
Radiation therapy in prostate cancer
 
image guided brachytherapy carcinoma cervix
image guided brachytherapy carcinoma cerviximage guided brachytherapy carcinoma cervix
image guided brachytherapy carcinoma cervix
 
Head and neck reirradiation
Head and neck reirradiationHead and neck reirradiation
Head and neck reirradiation
 
ICRU CONCEPT
ICRU CONCEPTICRU CONCEPT
ICRU CONCEPT
 
Radiotherapy for Prostate Cancer
Radiotherapy for Prostate CancerRadiotherapy for Prostate Cancer
Radiotherapy for Prostate Cancer
 
LUNG SBRT A LITERATURE REVIEW
LUNG SBRT A LITERATURE REVIEWLUNG SBRT A LITERATURE REVIEW
LUNG SBRT A LITERATURE REVIEW
 

Semelhante a Role of radiation in small cell lung cancer

Early stage lung_cancer- jtl
Early stage lung_cancer- jtlEarly stage lung_cancer- jtl
Early stage lung_cancer- jtl
John Lucas
 
Esophageal cancer-role of RT
Esophageal cancer-role of RTEsophageal cancer-role of RT
Esophageal cancer-role of RT
Bharti Devnani
 
Head And Neck Squamous Cell Carcinoma
Head And Neck Squamous Cell CarcinomaHead And Neck Squamous Cell Carcinoma
Head And Neck Squamous Cell Carcinoma
fondas vakalis
 
MON 2011 - Slide 14 - J.B. Vermorken - Systemic therapy
MON 2011 - Slide 14 - J.B. Vermorken - Systemic therapyMON 2011 - Slide 14 - J.B. Vermorken - Systemic therapy
MON 2011 - Slide 14 - J.B. Vermorken - Systemic therapy
European School of Oncology
 
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapyMCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
European School of Oncology
 
Locally Advanced Nsclc
Locally Advanced NsclcLocally Advanced Nsclc
Locally Advanced Nsclc
fondas vakalis
 
Radiotherapy Planning For Esophageal Cancers
Radiotherapy Planning For Esophageal CancersRadiotherapy Planning For Esophageal Cancers
Radiotherapy Planning For Esophageal Cancers
fondas vakalis
 

Semelhante a Role of radiation in small cell lung cancer (20)

Pyriform sinus tumours principles of management
Pyriform sinus tumours principles of managementPyriform sinus tumours principles of management
Pyriform sinus tumours principles of management
 
Early stage lung_cancer- jtl
Early stage lung_cancer- jtlEarly stage lung_cancer- jtl
Early stage lung_cancer- jtl
 
Small cell lung carcinoma
Small cell lung carcinomaSmall cell lung carcinoma
Small cell lung carcinoma
 
management of advanced cervical cancer [Autosaved].pptx
management of advanced cervical cancer [Autosaved].pptxmanagement of advanced cervical cancer [Autosaved].pptx
management of advanced cervical cancer [Autosaved].pptx
 
Radiation Therapy in the Management of Lung Cancer
Radiation Therapy in the Management of Lung CancerRadiation Therapy in the Management of Lung Cancer
Radiation Therapy in the Management of Lung Cancer
 
Role of RT in oropharynx ca 2013 june
Role of RT in oropharynx ca 2013 juneRole of RT in oropharynx ca 2013 june
Role of RT in oropharynx ca 2013 june
 
Rectal cancer
Rectal cancer Rectal cancer
Rectal cancer
 
Management ca esophagus sneha
Management ca esophagus snehaManagement ca esophagus sneha
Management ca esophagus sneha
 
SBRT in head and neck cancer
SBRT in  head and neck cancerSBRT in  head and neck cancer
SBRT in head and neck cancer
 
Small cell lung cancer staging and management
Small cell lung cancer staging and  managementSmall cell lung cancer staging and  management
Small cell lung cancer staging and management
 
SBRTweb.nearmc
SBRTweb.nearmcSBRTweb.nearmc
SBRTweb.nearmc
 
Esophageal cancer-role of RT
Esophageal cancer-role of RTEsophageal cancer-role of RT
Esophageal cancer-role of RT
 
Head And Neck Squamous Cell Carcinoma
Head And Neck Squamous Cell CarcinomaHead And Neck Squamous Cell Carcinoma
Head And Neck Squamous Cell Carcinoma
 
Hypofractionation in hnc
Hypofractionation in hncHypofractionation in hnc
Hypofractionation in hnc
 
MON 2011 - Slide 14 - J.B. Vermorken - Systemic therapy
MON 2011 - Slide 14 - J.B. Vermorken - Systemic therapyMON 2011 - Slide 14 - J.B. Vermorken - Systemic therapy
MON 2011 - Slide 14 - J.B. Vermorken - Systemic therapy
 
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapyMCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
 
Locally Advanced Nsclc
Locally Advanced NsclcLocally Advanced Nsclc
Locally Advanced Nsclc
 
Management of Rectal Carcinoma
Management of Rectal Carcinoma Management of Rectal Carcinoma
Management of Rectal Carcinoma
 
Small Cell Lung Cancer
Small Cell Lung CancerSmall Cell Lung Cancer
Small Cell Lung Cancer
 
Radiotherapy Planning For Esophageal Cancers
Radiotherapy Planning For Esophageal CancersRadiotherapy Planning For Esophageal Cancers
Radiotherapy Planning For Esophageal Cancers
 

Mais de Bharti Devnani

Technical issues in breast radiotherapy
Technical issues in breast radiotherapyTechnical issues in breast radiotherapy
Technical issues in breast radiotherapy
Bharti Devnani
 
managment of neck nodes with occult primary
managment of neck nodes with occult primarymanagment of neck nodes with occult primary
managment of neck nodes with occult primary
Bharti Devnani
 
Role of radiation in carcinoma rectum and colon
Role of radiation in carcinoma rectum and colon Role of radiation in carcinoma rectum and colon
Role of radiation in carcinoma rectum and colon
Bharti Devnani
 
Hypoxic cell sensitisers
Hypoxic cell sensitisersHypoxic cell sensitisers
Hypoxic cell sensitisers
Bharti Devnani
 

Mais de Bharti Devnani (16)

Predictors of duodenal toxicity in Carcinoma Pancreas
Predictors of duodenal toxicity in Carcinoma PancreasPredictors of duodenal toxicity in Carcinoma Pancreas
Predictors of duodenal toxicity in Carcinoma Pancreas
 
Clinical quality assurance in Radiotherapy
Clinical quality assurance in RadiotherapyClinical quality assurance in Radiotherapy
Clinical quality assurance in Radiotherapy
 
Carcinoma of unknown primary devnani
Carcinoma of unknown primary devnaniCarcinoma of unknown primary devnani
Carcinoma of unknown primary devnani
 
Breast cancer quiz (For Radiation Oncology residents)
Breast cancer quiz (For Radiation Oncology residents)Breast cancer quiz (For Radiation Oncology residents)
Breast cancer quiz (For Radiation Oncology residents)
 
postmastectomy radiotherapy after neo adjuvant chemotherapy in breast cancer
postmastectomy radiotherapy  after neo adjuvant chemotherapy in breast cancerpostmastectomy radiotherapy  after neo adjuvant chemotherapy in breast cancer
postmastectomy radiotherapy after neo adjuvant chemotherapy in breast cancer
 
Cross trial esophagus updated result
Cross trial esophagus updated resultCross trial esophagus updated result
Cross trial esophagus updated result
 
Omission of RT in elderly breast cancer patients
Omission of RT in  elderly breast cancer patientsOmission of RT in  elderly breast cancer patients
Omission of RT in elderly breast cancer patients
 
SBRT in lung cancer
SBRT in lung cancerSBRT in lung cancer
SBRT in lung cancer
 
Male breast cancer and occult primary
Male breast cancer and occult primaryMale breast cancer and occult primary
Male breast cancer and occult primary
 
ICRU reports 50 and 62
ICRU reports 50 and 62ICRU reports 50 and 62
ICRU reports 50 and 62
 
Accelerated partial breast irradiation
Accelerated partial breast irradiationAccelerated partial breast irradiation
Accelerated partial breast irradiation
 
Technical issues in breast radiotherapy
Technical issues in breast radiotherapyTechnical issues in breast radiotherapy
Technical issues in breast radiotherapy
 
managment of neck nodes with occult primary
managment of neck nodes with occult primarymanagment of neck nodes with occult primary
managment of neck nodes with occult primary
 
Radioprotectors
RadioprotectorsRadioprotectors
Radioprotectors
 
Role of radiation in carcinoma rectum and colon
Role of radiation in carcinoma rectum and colon Role of radiation in carcinoma rectum and colon
Role of radiation in carcinoma rectum and colon
 
Hypoxic cell sensitisers
Hypoxic cell sensitisersHypoxic cell sensitisers
Hypoxic cell sensitisers
 

Último

Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
QucHHunhnh
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
negromaestrong
 

Último (20)

ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docx
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 

Role of radiation in small cell lung cancer

  • 1. ROLE OF RADIATION IN SMALL CELL LUNG CANCER Dr Bharti Devnani Moderator:- Dr Sheh Rawat
  • 2. Staging of SCLC depends on radiation portals (Veteran’s administration lung group) Limited Stage Disease confined to I/L hemithorax which could be safely encompassed with in a tolerable RT field. T1, T2, nonmetastatic  Contralateral mediastinal and I/L SCF Extensive stage Beyond I/L hemithorax T3,T4 and metastatic disease
  • 3. Definitive (For LS) Thoracic radiation as a part of CCRT Adjuvant RT Node positive cases after lobectomy Prophylactic cranial irradiation Palliative EXRT Thoracic Brain mets Bone mets Oncologic emergencies SVCO Spinal cord compression Palliative brachytherapy Endobronchial brachytherapy: Hemoptysis
  • 4. ROLE OF THORACIC RADIATION IN LIMITED STAGE
  • 5. EVOLUTION Before the introduction of chemo in 1970, RT was the mainstay of treatment CT More local recurrences with chemo alone CT+RT-Standarad of care
  • 6. EVIDENCE FOR THORACIC RADIOTHERAPY 25-30% reduction in the local recurrence with 5-7% increase in 2 year survival with addition of radiotherapy Pignon et al NEJM 1992 327;1618-24
  • 7. ISSUES IN THORACIC RT OF SCLC  Sequencing with chemotherapy (concurrent v/s sequential)  Timing of RT (Early v/s late)  Portals (before chemotherapy v/s shrinking field)  Dose and fractionation schedules (conventional v/s hyperfractionation)
  • 8. ISSUES IN THORACIC RT OF SCLC  Sequencing with chemotherapy (concurrent v/s sequential)  Timing of RT (Early v/s late)  Portals (before chemotherapy v/s shrinking field)  Dose and fractionation schedules (conventional v/s hyperfractionation)
  • 9. Takada et al.J Clin Oncol 2002; 20:3054-60. Better outcome with CCT with a trend towards improved OS. Concurrent RT reduces the risk of tumor repopulation and development of resistant clones. Radiosensitizing effect
  • 10. ISSUES IN THORACIC RT OF SCLC  Sequencing with chemotherapy (concurrent v/s sequential)  Timing of RT (Early v/s late)  Portals (before chemotherapy v/s shrinking field)  Dose and fractionation schedules (conventional v/s hyperfractionation)
  • 11. Benefit in 2 year survival rate with early RT(within 9 weeks or before 3rd cycle)
  • 12. Factors which have significant impact on the benefit of early RT were:-  Type of chemotherapy  The fractionation scheme
  • 13. Concept of SER Start of any treatment until the end of radiotherapy
  • 14. Cancer Treat Rev 2007; 33:461-73.  Significant 2 & 5 years improvement in survival when RT was started within 30 days of platinum based chemo (2-year survival: HR: 0.73, 5-year survival: HR: 0.65).  This was even more pronounced when the overall treatment time of chest radiotherapy was less than 30 days.
  • 15. Early and concurrent chemoradiation is preferred over late and sequential schedule.
  • 16. ISSUES IN THORACIC RT OF SCLC  Sequencing with chemotherapy (concurrent v/s sequential)  Timing of RT (Early v/s late)  Dose and fractionation schedules (conventional v/s hyperfractionation)  Portals (before chemotherapy v/s shrinking field)
  • 17. High chances of local recurrence with conventional RT, attempts made to improve the outcome by:- Hyperfractionated Accelerated radiotherapy Dose escalation
  • 18. 417 patients LS- SCLC 45 Gy at 1.5 Gy/#B.D.x3weeks 45 Gy/25# at 1.8 Gy/# x5 weeks Grade -3 Esophagitis (27%v/s 11%) P<0.001
  • 20. ISSUES IN THORACIC RT OF SCLC  Sequencing with chemotherapy (concurrent v/s sequential)  Timing of RT (Early v/s late)  Dose and fractionation schedules (conventional v/s hyperfractionation)  Portals (before chemotherapy v/s shrinking field)
  • 21. RT PORTALS  PET based planning should be used. (PET at the time of radiotherapy planning or within 4 weeks)  GTV = Post induction chemotherapy volume  Omission of elective nodal irradition.  Low rates of local recurrence(11% with only CT based planning, 3 % with PET based planning)  Decreases the esophageal toxicity significantly.
  • 22. ROLE OF THORACIC RT IN EXTENSIVE STAGE
  • 23. CR at distant sites and any response at local site (n=210) CT + RT= 54 Gy/36# CT alone Median survival-17 months v/s 11 months Survival rate at 3 years-22% v/s 13% Survival rate at 5 years-9% v/s 4%
  • 24.
  • 26. Rationale  Frequent brain mets in SCLC  20 %- at diagnosis  80%- during the course of the disease  Once symptomatic- results have been poor.
  • 27. Incidence of brain metastasis decreased by 25% at 3 years (58.6% v/s 33.3%) 5.4 % survival benefit with addition of PCI
  • 28. PCI IN EXTENSIVE STAGE DISEASE 14.6 % v/s 40.4% 27.1% v/s 13.3% at 1 yr
  • 29. DOSE OF PCI Limited stage 25 Gy/10# 24 Gy/8# 30Gy/15# Extensive stage 25 Gy/10# Shorter fractionation scheme of 20 Gy/5# can be used. Dose>30 Gy should be avoided due to high risk of neurotoxicity
  • 30. ROLE OF RT IN ADJUVANT SETTING
  • 31.
  • 32. ROLE OF RT IN PALLIATION (EXRT)
  • 33. RADIATION FOR BRAIN METASTASIS WBRT- 30Gy/10#
  • 34. BONE METS & PATHOLOGICAL FRACTURE 30 Gy/10# 20Gy/5# 24Gy/6# 8 Gy single fraction
  • 35. ROLE OF RADIATION IN ONCOLOGIC EMERGENCIES IN SCLC
  • 37. SUPERIOR VENA CAVA OBSTRUCTION  Symptomatic relief in 70-90% cases with radiotherapy alone.  Dose- initial high dose fractionation of 3- 4 Gy followed by 1.8 Gy fractionation
  • 39.
  • 40.
  • 42. LS-SCLC Concurrent CCT/RT Early(1st or 2nd cycle) Dose-45 Gy @1.5 Gy bd or 50-60 Gy @1.8 Gy once daily Any response to chemo-PCI to a dose of 25 Gy/10# ES-SCLC Any response to chemo- PCI-25 Gy/10# or shorter 20 Gy/5# can be used. Possible value of local RT are the subject of ongoing investigation. Palliation
  • 44.
  • 45.  Santa air hostess se-aapki shakal meri biwi se milti hai  Air hostess ne zordar thappad santa k muh pe mara  Santa- Kamal hai, Aadat bhi milti hai
  • 46. Very Touchy story: "Husband forgot to wish her on his Wife's birthday. He came home late at night from the office ..... His wife shouted: How would u feel if u dont see me for next few days? He couldnt believe his luck. He replied at once.'' Wowww.....That would be great..!'' Monday passed & he didn't see her. Tuesday he didnt see her . . & wednesday passed too . . On Thursday the swelling was better & he could see her from the corner of his left eye...

Notas do Editor

  1. Contralateral SCF and contralateralhilar excluded from the limited study in many studies. s
  2. A 1992 meta-analysis evaluated randomized trials in which more than 2,100 patients with limited-stage SCLC were randomized to receive either chemotherapy alone or in combination with chest irradiation.236 Patients given combined modality therapy had a 14% reduction in death rate and an absolute 5.4% improvement in 3-year survival compared with those who received chemotherapy alone. Both differences were highly significant in this meta-analysis.(pignon and warde)
  3. 25-217 days
  4. We treated 231 patients withLS-SCLC. TRT consisted of 45 Gy over 3 weeks (1.5 Gytwice daily), and the patients were randomly assignedto receive either sequential or concurrent TRT. All patientsreceived four cycles of cisplatin plus etoposideevery 3 weeks (sequential arm) or 4 weeks (concurrentarm). TRT was begun on day 2 of the first cycle ofchemotherapy in the concurrent arm and after thefourth cycle in the sequential arm.Results: Concurrent radiotherapy yielded better survivalthan sequential radiotherapy (P .097 by logranktest). The median survival time was 19.7 monthsin the sequential arm versus 27.2 months in the concurrentarm. The 2-, 3-, and 5-year survival rates forpatients who received sequential radiotherapy were35.1%, 20.2%, and 18.3%, respectively, as opposed to54.4%, 29.8% and 23.7%, respectively, for the patientswho received concurrent radiotherapy. Hematologictoxicity was more severe in the concurrent arm. However,severe esophagitis was infrequent in both arms,occurring in 9% of the patients in the concurrent armand 4% in the sequential arm. Takada et al. (4) demonstrated that concurrent treatmentled to better outcomes than sequential. However, their studywas underpowered to demonstrate a survival benefit (114 patientsin each arm), but it did show a tendency for improvedsurvival (median 27 vs. 20 months; p &lt; .10) with concurrenttreatment. The improved outcome was accompanied by a significantincrease in Grade 3 or greater leukopenia (85% vs.54%) (
  5. This suggests that in the setting of combined-modality treatment, modest changes in treatment delivery can result in clinically significant changes in outcome.
  6. investigators showed that a shorter interval between the first day of chemotherapy administration and the last day of RT was associated with improved survival (12), indicating that accelerated tumor repopulation plays an important role.